IL-15-based fusions to IL-12 and IL-18

Patent metadata

Field	Value
Publication number	US-12233116-B2
Application number	US-202418896286-A
Country	US
Kind code	B2
Filing date	Sep 25, 2024
Priority date	Mar 6, 2017
Publication date	Feb 25, 2025
Grant date	Feb 25, 2025

Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

First claim

What is claimed is:

1. A pharmaceutical composition comprising natural killer (NK) cells and
an isolated soluble fusion protein complex comprising a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and an IL-18 polypeptide domain, and a second soluble protein comprising a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and an IL-12 polypeptide domain, wherein the IL-15 polypeptide domain binds to the IL-15RαSu polypeptide domain to form the soluble fusion protein complex,

wherein the pharmaceutical composition is formulated for administration.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for administration by instillation into the bladder, or subcutaneous, intravenous, intraperitoneal, intramuscular, intratumoral or intradermal injection.

3. The pharmaceutical composition of claim 1 , wherein the composition further comprises an immunotherapy, an adoptive cell therapy, a vaccine, an antibody, radiation therapy, or a chemotherapy.

4. The pharmaceutical composition of claim 3 , wherein the antibody is specific for a checkpoint inhibitor, a neoantigen, a tumor associated antigen, or a tumor specific antigen.

5. The pharmaceutical composition of claim 1 , wherein the isolated soluble fusion protein complex is formulated in an amount between 1 mg/kg and 100 mg/kg.

6. The pharmaceutical composition of claim 1 , wherein the NK cells are formulated in an amount of 1×10 4 cells/kg and 1×10 10 cells/kg.

Assignees

• Altor Bioscience Llc

Inventors

• Marcus Warren D
• Newman Robert
• Liu Bai
• You Lijing
• Kong Lin
• Rhode Peter
• Wong Hing C

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K14/7155

  for interleukins [IL] · CPC title

• C07K14/54

  Interleukins [IL] · CPC title

• C07K14/5443 Primary

  IL-15 · CPC title